ReviewCurrent drug targets2015
Molecular pathophysiology of priapism: emerging targets.
Review in Current drug targets, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05142254 (A Randomized Controlled Double-Blind Trial for Prevention of Recurrent Ischemic Priapism in Men With Sickle Cell Disease), which is not on this map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Controlled Double-Blind Trial for Prevention of Recurrent Ischemic Priapism in Men With Sickle Cell Disease: A Pilot Study
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- What is the effectiveness of surgical and non-surgical therapies in the treatment of ischemic priapism in patients with sickle cell disease? A systematic review by the EAU Sexual and Reproductive Health Guidelines Panel.International journal of impotence research · 2024Pooled it
- Update on the prevalence and pathophysiology of sickle cell priapism: a narrative review.International journal of impotence research · 2026Review
- Article
- Systemic sodium hydrosulfide (NaHS) administration mitigates reperfusion injury in an experimental model of ischemic priapism.World journal of urology · 2026Article
- Trazodone-Induced Ischemic Priapism Successfully Managed With Conservative Therapy: A Case Report.Cureus · 2025Article
- The endocannabinoid system's genetic polymorphisms in sickle cell anemia patients.Scientific reports · 2024Article
- Epidemiology and treatment of priapism in sickle cell disease.Hematology. American Society of Hematology. Education Program · 2022Review
- Review of Ischemic and Non-ischemic Priapism.Current urology reports · 2022Review
- Article
- Penile Prosthesis Implantation in Refractory Ischaemic Priapism: Patient Selection and Special Considerations.Research and reports in urology · 2022Review
- Resveratrol-nitric oxide donor hybrid effect on priapism in sickle cell and nitric oxide-deficient mouse.PloS one · 2022Article
- A visualization system for erectile vascular dynamics.Frontiers in cell and developmental biology · 2022Article
- Risk Factors for Surgical Shunting in a Large Cohort With Ischemic Priapism.The journal of sexual medicine · 2020Article
- Prevalence of priapism in individuals with sickle cell disease and implications on male sexual function.Einstein (Sao Paulo, Brazil) · 2020Article
- Priapism, hemoglobin desaturation, and red blood cell adhesion in men with sickle cell anemia.Blood cells, molecules & diseases · 2019Article
- Article
- Neuroprotective and Nerve Regenerative Approaches for Treatment of Erectile Dysfunction after Cavernous Nerve Injury.International journal of molecular sciences · 2017Review
- Management of refractory ischemic priapism: current perspectives.Research and reports in urology · 2017Review
- Nitrergic Mechanisms for Management of Recurrent Priapism.Sexual medicine reviews · 2015Article
- How I treat priapism.Blood · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Priapism is an erectile disorder involving uncontrolled, prolonged penile erection without sexual purpose, which can lead to erectile dysfunction. Ischemic priapism, the most common of the variants, occurs with high prevalence in patients with sickle cell disease. Despite the potentially devastating complications of this condition, management of recurrent priapism episodes historically has commonly involved reactive treatments rather than preventative strategies. Recently, increasing elucidation of the complex molecular mechanisms underlying this disorder, principally involving dysregulation of nitric oxide signaling, has allowed for greater insights and exploration into potential therapeutic targets. In this review, we discuss the multiple molecular regulatory pathways implicated in the pathophysiology of priapism. We also identify the roles and mechanisms of molecular effectors in providing the basis for potential future therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.